A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

P

Pharmacia & Upjohn

Status and phase

Completed
Phase 2

Conditions

HIV Infections

Treatments

Drug: Delavirdine mesylate

Study type

Interventional

Funder types

Industry

Identifiers

NCT00002210
228D
0069

Details and patient eligibility

About

The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.

Sex

All

Ages

1 month to 15 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients must have:

  • HIV infection.
  • Plasma HIV-1 levels greater than 10,000 copies/ml.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems